News & Resources

Cernostics Announces Scientific Presentations at DDW and ISPOR Meetings Demonstrating Clinical Validation and Cost-Effectiveness of New TissueCypher® Barrett's Esophagus Assay

Test Predicts Development of Esophageal Cancer in Patients with Barrett's Esophagus

 

Bethlehem, PA – May 11, 2016. Cernostics, Inc. today announced that findings from three scientific studies of its new TissueCypher® Barrett's Esophagus Assay will be presented at the Digestive Disease Week (DDW) meeting in San Diego. DDW is the world's largest conference on Gastro-intestinal Medicine and the ideal place for physicians to view data supporting the reliability and cost-effectiveness of Cernostics' TissueCypher® Barrett's Esophagus Assay— the first clinical assay of its kind to predict the risk of developing esophageal cancer.  "We are delighted that DDW has recognized the significance of the clinical data supporting our TissueCypher® Barrett's Esophagus Assay" commented Mike Hoerres, Cernostics, Inc. CEO.  "And Gastroenterologists will be pleased to learn that the test identifies high risk patients that are 9x more likely to progress to high grade dysplasia or cancer within five years of biopsy, providing a new tool to improve clinical decision making," he added.  

 

DDW attendees are invited to visit Cernostics at Exhibit Booth #551, or attend the scientific

presentations listed below:

 

A Novel Tissue Systems Pathology Test Predicts

Progression in Barrett’s Esophagus Patients
Session Type: Podium Presentation #301
Session Title: Barrett’s Esophagus: Diagnosis, Management
and Surveillance
Date: May 22, 2016 Time: 10:45 – 11:00 a.m. Location: SDCC Rm 10

 

A Tissue Systems Pathology Test Detects a Field

Effect Associated With High Grade Dysplasia and
Esophageal Cancer in Barrett’s Esophagus Patients
Session Type: Poster Session
Session Title: Barrett’s Esophagus: Diagnosis, Management
and Surveillance (Sa1257)
Date: May 21, 2016 Time: Noon – 2:00 p.m. Location: Hall C

 

A Cost-Effectiveness Analysis of a Cancer Risk

Prediction Test for Patients with Barrett’s
Esophagus
Session Type: Poster Session
Session Title: Barrett’s Esophagus: Diagnosis, Management
and Surveillance (Sa1261)
Date: May 21, 2016 Time: Noon – 2:00 p.m. Location: Hall C

 

PLEASE NOTE: Scientific colleagues from Geisinger will be making the following presentation at the ISPOR meeting (International Society for Pharmacoeconomics & Outcomes Research) in Washington DC on May 23.

 

A Cost-Effectiveness Analysis of a Test That
Predicts Risk of Malignant Progression in
Barrett’s Esophagus
Session Type: Podium Presentation Session II (CN4)
Session Title: Cancer Outcomes Studies
Date: May 23, 2016 Time: 3:45 pm- 4:45 p.m.

 

For additional information please visit www.cernostics.com

Contact: Josh Weinstein
jwEinstein Strategic Messaging, Inc.
610-438-8853 jw@jweinstein.guru

Customer Service

Mon-Fri 9am-5pm (EST)

×